Idiopathic thrombocytopenic purpura (ITP) is a common disease in pediatrics, which is characterized by significant reduction of platelets and bleeding from the skin, mucous membranes and even organs. The current treatment is mostly based on immunosuppressive therapy. However, in clinical work we can often encounter this kind of patients, who must pursue platelet count increase to the level of normal people, and this attitude is not desirable. The main function of platelets is to stop bleeding, and the main problem of ITP is also bleeding. We can easily understand that as long as the patient does not bleed, it is not enough. Why must the platelets be raised to normal? Some patients may ask why not if it can be raised to a normal level. There is a problem of inconsistent perception between the doctor and the patient. Which perception is correct? Undoubtedly, the doctor is right. It is also wrong if a certain doctor must raise your platelets to normal levels and keep increasing the hormone dose or applying drugs like prednisone and Medrol for a long time in high doses. It is understandable that patients ask for raising their platelets to normal levels. However, we should recognize that for some patients, this may require an increased dose of prednisone or a larger dose over time to maintain, with resulting side effects that we cannot accept. Such as infections due to the patient’s reduced resistance, edema due to the long-term application of corticosteroids, the appearance of full moon faces and buffalo waists, facial acne, and even osteoporosis and femoral head necrosis, and all of these side effects are far more harmful than platelet reduction. This is typical of the dangers associated with overmedication. ITP is an autoimmune benign disease for which there is no complete cure, and the goal of ITP treatment is to raise the patient’s platelet count to a safe range to prevent severe bleeding and reduce the death rate, not to bring the platelet count to a normal range. Therefore, in clinical practice, if the platelet count is greater than 20×109/L, there is no bleeding manifestation, and the patient is not engaged in work or activities that increase the risk of bleeding, the patient may not be treated, but should be followed up and observed. If the platelet count is below 20×109/L, or if there are bleeding symptoms, therapeutic intervention is required. Therefore, for patients who do not need therapeutic intervention, overtreatment not only fails to control the disease, but also increases the incidence of complications and even endangers the patient’s life.